Related Experiment Video
Updated: Jul 1, 2026

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
Published on: March 1, 2019
A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression
Nathalie Berteaux1, Nathalie Aptel, Guy Cathala
1INSERM U908, Université des Sciences et Technologies de Lille, Bâtiment SN3, 59655 Villeneuve d'Ascq Cedex, France.
Abstract:
The H19/IGFf2 locus belongs to a large imprinted domain located on human chromosome 11p15.5 (homologue to mouse distal chromosome 7). The H19 gene is expressed from the maternal allele, while IGF2 is paternally expressed. Natural antisense transcripts and intergenic transcription have been involved in many aspects of eukaryotic gene expression, including genomic imprinting and RNA interference. However, apart from the identification of some IGF2 antisense transcripts, few data are available on that topic at the H19/IGF2 locus. We identify here a novel transcriptional activity at both the human and the mouse H19/IGF2 imprinted loci. This activity occurs antisense to the H19 gene and has the potential to produce a single 120-kb transcript that we called the 91H RNA. This nuclear and short-lived RNA is not imprinted in mouse but is expressed predominantly from the maternal allele in both mice and humans within the H19 gene region. Moreover, the transcript is stabilized in breast cancer cells and overexpressed in human breast tumors. Finally, knockdown experiments showed that, in humans, 91H, rather than affecting H19 expression, regulates IGF2 expression in trans.
Related Concept Videos
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Inheritance of Chromatin Structures
lncRNA - Long Non-coding RNAs
piRNA - Piwi-interacting RNAs
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...